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O.R. & 95% CI
(GO : No GO)
Favourable:
CC 12/25 8/20 −1·0 4·9 0.82 (0.34, 1.98)
CT 5/18 6/12 −1·7 2·6 0.52 (0.15, 1.74)
TT 1/4 4/4 −1·9 1·2 0.19 (0.03, 1.19)
Subtotal: 18/47 18/36 −4·6 8·7 0.59 (0.30, 1.14)
P = 0·1
Test for heterogeneity between subgroups: χ22 = 2·0; P = 0·4                                                                             
Test for trend between subgroups: χ21 = 1·9; P = 0·2
Intermediate:
CC 42/69 36/58 −1·0 19·2 0.95 (0.61, 1.49)
CT 42/62 37/64 4·2 19·7 1.24 (0.80, 1.93)
TT 8/16 4/7 −0·9 2·3 0.68 (0.19, 2.47)
Subtotal: 92/147 77/129 2·3 41·2 1.06 (0.78, 1.44)
P = 0·7
Test for heterogeneity between subgroups: χ22 = 1·2; P = 0·6                                                                             
Test for trend between subgroups: χ21 = 0·1; P = 0·8
Adverse:
CC 14/14 8/8 −0·7 4·3 0.85 (0.33, 2.19)
CT 13/15 7/8 0·6 4·7 1.15 (0.46, 2.83)
TT 3/4 1/1 −0·8 0·2 0.01 (0.00, 0.90)
Subtotal: 30/33 16/17 −0·9 9·1 0.91 (0.48, 1.74)
P = 0·8
Test for heterogeneity between subgroups: χ22 = 4·1; P = 0·1                                                                             
Test for trend between subgroups: χ21 = 0·1; P = 0·8




Effect P = 0·7
Test for heterogeneity (9 groups): χ28 = 9·8; P = 0·3                                                                                    
Test for trend between subtotals: χ21 = 0·8; P = 0·4
Test for heterogeneity between subtotals: χ22 = 2·5; P = 0·3                                                                             
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O.R. & 95% CI
(GO : No GO)
Favourable:
CC 7/26 7/22 −0·8 3·4 0.79 (0.27, 2.27)
CT 4/18 6/13 −2·5 2·2 0.33 (0.09, 1.23)
TT 0/4 3/4 −1·6 0·7 0.12 (0.01, 1.12)
Subtotal: 11/48 16/39 −4·9 6·4 0.47 (0.22, 1.01)
P = 0·05
Test for heterogeneity between subgroups: χ22 = 2·7; P = 0·3                                                                             
Test for trend between subgroups: χ21 = 2·6; P = 0·1
Intermediate:
CC 38/75 40/67 −5·4 19·0 0.75 (0.48, 1.18)
CT 46/73 28/67 11·7 18·3 1.90 (1.20, 3.00)
TT 9/18 8/11 −2·6 3·7 0.49 (0.18, 1.38)
Subtotal: 93/166 76/145 3·7 40·9 1.10 (0.81, 1.49)
P = 0·6
Test for heterogeneity between subgroups: χ22 = 10·5; P = 0·005                                                                          
Test for trend between subgroups: χ21 = 1·1; P = 0·3
Adverse:
CC 15/16 14/14 −4·8 5·7 0.43 (0.19, 0.97)
CT 17/19 12/13 0·0 6·9 1.00 (0.48, 2.11)
TT 4/6 1/1 −0·5 0·4 0.31 (0.02, 6.40)
Subtotal: 36/41 27/28 −5·3 13·0 0.67 (0.39, 1.14)
P = 0·1
Test for heterogeneity between subgroups: χ22 = 2·5; P = 0·3                                                                             
Test for trend between subgroups: χ21 = 1·2; P = 0·3




Effect P = 0·4
Test for heterogeneity (9 groups): χ28 = 21·2; P = 0·007                                                                                 
Test for trend between subtotals: χ21 = 0·0; P = 0·9
Test for heterogeneity between subtotals: χ22 = 5·5; P = 0·06                                                                            
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(B)
	   1	  SUPPLEMENTAL	  DATA	  	  CD33	  SNP	  screening	  PCR	  products	  of	  266bp	  were	  generated	  from	  genomic	  DNA	  using	  BIOTAQ	  DNA	  polymerase	  (Bioline,	  London,	  UK)	  with	  manufacturer’s	  recommended	  conditions	  and	  primers	  CD33	  exon	  1/F	  (5’-­‐CTGGAAGCTGCTTCCTCAGACATG-­‐3’)	  and	  CD33	  exon	  2/D	  (5’-­‐GAACCAGTAACCATGAACTGGGGAGTT-­‐3’)	  at	  an	  annealing	  temperature	  of	  66oC.	  Products	  were	  digested	  overnight	  with	  HaeIII	  (New	  England	  Biolabs,	  Hitchin,	  UK)	  and	  separated	  on	  a	  2%	  agarose	  gel	  to	  discriminate	  between	  the	  C	  alleles	  (94	  +	  29	  +	  143bp)	  and	  T	  alleles	  (94	  +	  172bp).	  	   	  
	   2	  Supplemental	  Table	  1:	  Demographics	  according	  to	  genotype	  for	  the	  CD33	  SNP	  	  Parameter	   Total	  cohort	   CD33	  genotype	  	   P	  CC	  vs	  not	  CC	  	   	   CC	   CT	   TT	   	  Patients	   720	   336	  (47%)	   319	  (44%)	   65	  (9%)	   	  Median	  age,	  years	  	  (range)	   48	  	  (13-­‐69)	   48	  	  (16-­‐69)	   49	  	  (13-­‐68)	   49	  	  (19-­‐63)	   0.3	  Sex:	  	  	  	  	  	  Male	  	  	  	  	  	  Female	   	  395	  (55%)	  325	  (45%)	   	  178	  (53%)	  158	  (47%)	   	  180	  (56%)	  139	  (44%)	   	  37	  (57%)	  28	  	  (43%)	   0.3	  Diagnosis:	  	  	  	  	  	  De	  novo	  	  	  	  	  	  Secondary	  	  	  	  	  	  High	  risk	  MDS	  
	  642	  (89%)	  57	  (8%)	  21	  (3%)	  
	  304	  (90%)	  21	  (6%)	  11	  (3%)	  
	  282	  (88%)	  30	  (9%)	  	  7	  (2%)	  
	  56	  (86%)	  6	  (9%)	  3	  (5%)	  
0.3	  
WHO	  performance	  status:	  	  	  	  	  	  0	  	  	  	  	  	  1	  	  	  	  	  	  2	  	  	  	  	  	  3	  	  	  	  	  	  4	  
	  523	  (73%)	  175	  (24%)	  13	  (2%)	  7	  (1%)	  2	  (<1%)	  
	  235	  (70%)	  90	  (27%)	  7	  (2%)	  5	  (1%)	  2	  (<1%)	  
	  239	  (75%)	  71	  (22%)	  5	  (2%)	  4	  (1%)	  0	  
	  49	  (75%)	  14	  (22%)	  1	  (2%)	  1	  (2%)	  0	  
0.2	  
Median	  WBC,	  x109/L	  	  (range)	   11.3	  	  (0.3-­‐456.0)	   10.2	  (0.8-­‐456.0)	   12.2	  (0.3-­‐430.0)	   16.1	  (0.9-­‐256.3)	   0.3	  Cytogenetics	  (%	  of	  known):	  	  	  	  	  	  Favorable	  	  	  	  	  	  Intermediate	  	  	  	  	  	  Adverse	  	  	  	  	  	  Unknown	  
	  111	  (17%)	  436	  (68%)	  95	  (15%)	  78	  
	  57	  (19%)	  201	  (67%)	  41	  (14%)	  37	  
	  43	  (15%)	  197	  (69%)	  44	  (15%)	  35	  
	  11	  (19%)	  38	  (64%)	  10	  (17%)	  6	  
0.2	  
Median	  MFI	  for	  CD33	  blasts	  (range)	   9.4	  (0.1-­‐298.1)	   10.7	  (0.2-­‐298.1)	   11.1	  (0.1-­‐134.8)	   3.8	  (0.1-­‐13.3)	   0.1	  (0.0001	  across	  all	  groups)	  GO	  given	  No	  GO	  given	   448	  (62%)	  272	  (38%)	   203	  (61%)	  130	  (39%)	   198	  (62%)	  121	  (38%)	   44	  (68%)	  21	  (32%)	   	  	   	   	   	   	   	  Patients	  in	  the	  GO	  vs	  no	  GO	  randomization:	   536	   253	  (47%)	   233	  (43%)	   50	  (9%)	   	  Any	  SCT	  Allogeneic	  SCT	   299	  (56%)	  261	  (49%)	   144	  (57%)	  126	  (50%)	   124	  (53%)	  106	  (45%)	   31	  (62%)	  29	  (58%)	   	  	  Abbreviations:	  MFI,	  mean	  fluorescence	  intensity;	  SCT,	  stem	  cell	  transplant	  	  
Supplemental	Figure	S1.	Flow	chart	of	patients	included	in	the	study.	ADE,	daunorubicin+	
cytarabine+etoposide;	DA,	daunorubicin+cytarabine;	FLAG-Ida,	fludarabine,	cytarabine,	G-CSF,	idarubicin;	GO,	
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Supplemental	Figure	S2.	CD33	expression	levels	in	CD33-positive	blasts	according	to	the	
patients’	CD33	SNP	genotype.	MFI,	mean	fluorescence	intensity	
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Supplemental	Figure	3.	Overall	survival	according	to	CD33	SNP	genotype	in	
patients	randomized	to	receive	3mg/m2 or	6mg/m2 GO	
